MA41179A - Composés inhibiteurs de parg - Google Patents
Composés inhibiteurs de pargInfo
- Publication number
- MA41179A MA41179A MA041179A MA41179A MA41179A MA 41179 A MA41179 A MA 41179A MA 041179 A MA041179 A MA 041179A MA 41179 A MA41179 A MA 41179A MA 41179 A MA41179 A MA 41179A
- Authority
- MA
- Morocco
- Prior art keywords
- sub
- parg
- inhibitor compounds
- compounds
- parg inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La présente invention concerne des composés de la formule i qui fonctionnent en tant qu'inhibiteurs de l'activité enzymatique parg (poly adp-ribose glycohydrolase) : dans ladite formule, r<sub>1a</sub>, r<sub>1b</sub>, r<sub>1c</sub>, r<sub>1d</sub>, r<sub>1e</sub>, w, x<sub>1</sub>, x<sub>2</sub>, x<sub>3</sub>, x<sub>4</sub>, x<sub>5</sub>, x<sub>6</sub>, x<sub>7</sub>, c sont chacun tels que définis dans la description. La présente invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques les comprenant et leur utilisation dans le traitement de troubles prolifératifs, tels que le cancer, ainsi que d'autres maladies ou états dans lesquels est impliquée l'activité parg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201422771 | 2014-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41179A true MA41179A (fr) | 2017-10-24 |
Family
ID=54937310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041179A MA41179A (fr) | 2014-12-19 | 2015-12-16 | Composés inhibiteurs de parg |
Country Status (18)
Country | Link |
---|---|
US (3) | US10508086B2 (fr) |
EP (2) | EP3233845B1 (fr) |
JP (1) | JP6673920B2 (fr) |
KR (1) | KR20170095370A (fr) |
CN (2) | CN112979631A (fr) |
AU (1) | AU2015365602B2 (fr) |
BR (1) | BR112017012707B1 (fr) |
CA (1) | CA2969298C (fr) |
ES (1) | ES2886471T3 (fr) |
HK (1) | HK1245253A1 (fr) |
IL (1) | IL252745B (fr) |
MA (1) | MA41179A (fr) |
MX (1) | MX2017007976A (fr) |
NZ (1) | NZ732394A (fr) |
RU (1) | RU2017125520A (fr) |
SG (1) | SG11201704843QA (fr) |
WO (1) | WO2016097749A1 (fr) |
ZA (1) | ZA201704383B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
EP3947351A4 (fr) * | 2019-03-29 | 2022-12-07 | Board of Regents, The University of Texas System | Inhibiteurs de parg à petites molécules et leurs procédés d'utilisation |
EP4031249A1 (fr) * | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | Dérivés de sulfonamido d'indole et d'indazole substitués en position 4 en tant qu'inhibiteurs de parg |
AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
WO2023057394A1 (fr) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
US20230265057A1 (en) * | 2022-02-14 | 2023-08-24 | Arase Therapeutics Inc. | Inhibitors of parg |
WO2023165571A1 (fr) * | 2022-03-04 | 2023-09-07 | 上海璎黎药业有限公司 | Composé contenant une structure cyclique hétéroaromatique à cinq chaînons, composition pharmaceutique et utilisation associées |
WO2023175184A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer |
WO2023175185A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
US20230303556A1 (en) * | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
CN114685283B (zh) * | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | 一种1-(氟甲基)环丙胺盐酸盐的制备方法 |
WO2023205914A1 (fr) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Dérivés hétérocycliques tricycliques, compositions et utilisations de ceux-ci |
TW202400597A (zh) * | 2022-04-28 | 2024-01-01 | 大陸商北京丹擎醫藥科技有限公司 | 三環雜環衍生物,其組合物和應用 |
US11939335B2 (en) | 2022-05-17 | 2024-03-26 | 858 Therapeutics, Inc. | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG |
WO2024017306A1 (fr) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | Composé cyclique hétéroaromatique contenant du soufre, composition pharmaceutique de celui-ci et son utilisation |
EP4311829A1 (fr) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer |
WO2024074497A1 (fr) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Composé inhibiteur de parg |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1157858A (fr) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Derives de quinazoline |
DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
ES2351699T3 (es) | 1999-02-10 | 2011-02-09 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos. |
DE19927415A1 (de) * | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
JP2003535078A (ja) | 2000-05-31 | 2003-11-25 | アストラゼネカ アクチボラグ | 血管損傷活性のあるインドール誘導体 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
EP1301498A1 (fr) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Derives de colchinol utiles comme inhibiteurs de l'angiogenese |
TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
PL1719773T3 (pl) | 2004-02-24 | 2009-08-31 | Japan Tobacco Inc | Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV |
CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
WO2007014226A2 (fr) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Composes pour le traitement de neurodegenerescence et d'accident cerebro-vasculaire |
KR101126895B1 (ko) * | 2006-01-24 | 2012-03-20 | 일라이 릴리 앤드 캄파니 | 프로게스테론 수용체의 인돌 술폰아미드 조절제 |
JP2009530342A (ja) | 2006-03-20 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Btkおよびsyk蛋白キナーゼを阻害する方法 |
WO2009047255A1 (fr) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine |
CA2728098A1 (fr) * | 2008-07-17 | 2010-01-21 | Asahi Kasei Pharma Corporation | Composes tricycliques contenant du pyrazole en tant qu'antagonistes du recepteur ep1 |
CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
CA2786999A1 (fr) | 2010-01-13 | 2011-07-21 | Glaxosmithkline Llc | Composes et procedes |
JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インダゾール |
WO2011140442A1 (fr) | 2010-05-07 | 2011-11-10 | Glaxo Group Limited | Amino-quinoléines en tant qu'inhibiteurs de kinase |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
MX2013006101A (es) | 2010-12-17 | 2013-07-02 | Hoffmann La Roche | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos. |
EP2471363A1 (fr) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes |
JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
WO2013027168A1 (fr) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
WO2013067300A1 (fr) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement |
WO2014026327A1 (fr) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations |
KR101942151B1 (ko) | 2012-12-27 | 2019-01-24 | 드렉셀유니버시티 | Hbv 감염에 대한 항바이러스 물질 |
EP3105210B1 (fr) | 2014-02-11 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines comme inhibiteurs de midh1 |
MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
-
2015
- 2015-12-16 MA MA041179A patent/MA41179A/fr unknown
- 2015-12-17 CN CN202110213641.5A patent/CN112979631A/zh active Pending
- 2015-12-17 ES ES15813554T patent/ES2886471T3/es active Active
- 2015-12-17 EP EP15813554.1A patent/EP3233845B1/fr active Active
- 2015-12-17 US US15/533,819 patent/US10508086B2/en active Active
- 2015-12-17 CA CA2969298A patent/CA2969298C/fr active Active
- 2015-12-17 CN CN201580075709.0A patent/CN107295799B/zh active Active
- 2015-12-17 KR KR1020177019869A patent/KR20170095370A/ko not_active Application Discontinuation
- 2015-12-17 EP EP21179871.5A patent/EP3907224A1/fr active Pending
- 2015-12-17 WO PCT/GB2015/054064 patent/WO2016097749A1/fr active Application Filing
- 2015-12-17 MX MX2017007976A patent/MX2017007976A/es unknown
- 2015-12-17 NZ NZ732394A patent/NZ732394A/en unknown
- 2015-12-17 BR BR112017012707-5A patent/BR112017012707B1/pt active IP Right Grant
- 2015-12-17 JP JP2017532912A patent/JP6673920B2/ja active Active
- 2015-12-17 SG SG11201704843QA patent/SG11201704843QA/en unknown
- 2015-12-17 RU RU2017125520A patent/RU2017125520A/ru not_active Application Discontinuation
- 2015-12-17 AU AU2015365602A patent/AU2015365602B2/en active Active
-
2017
- 2017-06-07 IL IL252745A patent/IL252745B/en active IP Right Grant
- 2017-06-28 ZA ZA2017/04383A patent/ZA201704383B/en unknown
-
2018
- 2018-04-04 HK HK18104517.6A patent/HK1245253A1/zh unknown
-
2019
- 2019-10-24 US US16/662,997 patent/US10995073B2/en active Active
-
2021
- 2021-03-17 US US17/204,206 patent/US20210380539A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3233845A1 (fr) | 2017-10-25 |
WO2016097749A1 (fr) | 2016-06-23 |
RU2017125520A (ru) | 2019-01-21 |
AU2015365602A1 (en) | 2017-06-29 |
US20200165208A1 (en) | 2020-05-28 |
AU2015365602B2 (en) | 2020-02-27 |
JP6673920B2 (ja) | 2020-03-25 |
EP3233845B1 (fr) | 2021-07-21 |
US10995073B2 (en) | 2021-05-04 |
ZA201704383B (en) | 2022-03-30 |
EP3907224A1 (fr) | 2021-11-10 |
US20210380539A1 (en) | 2021-12-09 |
IL252745B (en) | 2020-03-31 |
US10508086B2 (en) | 2019-12-17 |
US20180194738A1 (en) | 2018-07-12 |
CN107295799B (zh) | 2021-03-16 |
BR112017012707B1 (pt) | 2023-10-24 |
RU2017125520A3 (fr) | 2019-06-06 |
ES2886471T3 (es) | 2021-12-20 |
KR20170095370A (ko) | 2017-08-22 |
MX2017007976A (es) | 2018-03-26 |
IL252745A0 (en) | 2017-08-31 |
HK1245253A1 (zh) | 2018-08-24 |
SG11201704843QA (en) | 2017-07-28 |
CN112979631A (zh) | 2021-06-18 |
CA2969298C (fr) | 2023-10-17 |
CA2969298A1 (fr) | 2016-06-23 |
CN107295799A (zh) | 2017-10-24 |
BR112017012707A2 (pt) | 2018-01-02 |
NZ732394A (en) | 2024-01-26 |
JP2017538750A (ja) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41179A (fr) | Composés inhibiteurs de parg | |
MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
EA201892666A1 (ru) | 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
MA34969B1 (fr) | Composes et compositions en tant qu inibiteurs de trk | |
MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
MA38648B1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA37691A1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues |